Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

US Patent 9422556 · Granted Aug 23, 2016

Estimated economic value: $7,136,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Adeno-associated virus (AAV) systems for treatment of genetic hearing loss2025
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2023
Devices, systems, and methods for modeling ocular translaminar pressure gradient2023
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2022
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2022
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2021
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)2021
Ocular formulations for drug-delivery to the posterior segment of the eye2019
Ocular formulations for drug-delivery to the posterior segment of the eye2019
Ocular formulations for drug-delivery and protection of the anterior segment of 2019
Ocular formulations for drug-delivery and protection of the anterior segment of 2019
Transferrin/transferrin receptor-mediated siRNA delivery2018